A comparative study between platelet-rich plasma and platelet-poor plasma effects on angiogenesis

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Biotechnology

Background:

• Platelet-rich plasma (PRP) is recognized for its role in therapeutic angiogenesis.
• Understanding the comparative angiogenic potential of PRP and platelet-poor plasma (PPP) is crucial for optimizing regenerative therapies.

Purpose of the Study:

• To compare the in vitro and in vivo angiogenic effects of PRP versus PPP.
• To evaluate the impact of PRP and PPP on key angiogenic markers, including VEGFR2 and CD34 expression.

Main Methods:

• In vitro studies using human umbilical vein endothelial cells (HUVECs).
• In vivo studies utilizing rat skin models.
• Analysis of VEGFR2 and CD34 expression via real-time PCR, flow cytometry, Western blot, and immunocytochemistry.

Main Results:

• Both PRP and PPP significantly influenced VEGFR2 and CD34 expression in HUVECs, with a more pronounced effect observed with PPP.
• In vivo studies revealed an earlier angiogenic response with PPP compared to PRP.
• The study presents the first direct comparison of PRP and PPP for angiogenic potential.

Conclusions:

• PRP and PPP exhibit distinct angiogenic properties, influencing endothelial cell marker expression and in vivo neovascularization.
• While both plasma fractions promote angiogenesis, PPP demonstrates a faster onset of angiogenic effects in vivo.
• Further research is necessary to elucidate the mechanisms underlying these differential effects and enhance therapeutic applications.